co-blockade,patientswithhigh-gradeneuroendocrinecarcinomas(NEC) had an ORR of 44% (8/18patients) vs.0%inlow/intermediate grade NET (0/14 patients; p = 0.004)(8), whileamong40NENpatientsenrolledinamultiple-centerphaseIbtrial ofanti-PD-1 (toripalimab), poorly-differentiated NEC andwell-differentiated NET subgroups had similarresponserates(ORR: 18.7%vs.25.0%)(9).However,T-NENhavebarelybeenincludedinpreviousandongoingclinicaltrialsduetoitsrarity.